79家医院成国家可信评价点，真实世界研究助力医保科学决策

Core Viewpoint - The establishment of the "National Credible Evaluation Point Network for Real-World Comprehensive Value Assessment of Medical Insurance" marks a significant step in integrating real-world data into China's medical insurance decision-making process, creating a new "value metric" for evaluating the clinical effectiveness and overall impact of medical products on patient quality of life and resource allocation [1][2][4]. Group 1: Establishment of the Network - A total of 79 medical institutions signed the agreement to form the credible evaluation point network, which will play a crucial role in supporting scientific decision-making for medical insurance [1][2]. - The network is designed to be open and dynamic, allowing for the inclusion of additional institutions based on their research achievements and contributions to the evaluation process [6]. Group 2: Evaluation Framework - The National Medical Insurance Administration has drafted guidelines for the real-world comprehensive value assessment of drugs, which outline the evaluation objects, processes, and methodological frameworks [2][5]. - The shift from traditional theoretical models to evaluations based on clinical real-world data signifies a transformation in the medical insurance evaluation system [2]. Group 3: Impact on Medical Institutions - Medical institutions involved in the network will be responsible for generating data, establishing standards, and conducting research, thereby playing an irreplaceable role in the evaluation process [4][6]. - The network aims to fill the gap in real-world research that has previously been lacking, ensuring that the clinical application of drugs and medical supplies is adequately studied [6]. Group 4: Future Implications for Pharmaceutical Companies - Real-world comprehensive value assessments will provide objective evidence for medical insurance decision-making, influencing the dynamic adjustment of the medical insurance catalog [9]. - Pharmaceutical companies are encouraged to conduct real-world studies during the critical period between clinical trials and drug applications to provide more evidence for insurance decisions [9][10]. - The establishment of incentive mechanisms linked to insurance negotiations will motivate pharmaceutical companies to engage in real-world value assessments, impacting future negotiations and payment standards [10].